Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition

Lastly, MIRM is also working on PBC and PSC treatments. For PBC, trials showed a 3.8-point reduction from baseline in the primary endpoint of pruritus, indicating a significant improvement in reducing this primary symptom of PBC. For PSC, outcomes were also encouraging, preliminary meeting efficacy thresholds that need to be confirmed in further studies with 20mg daily doses. Quality at a Premium: Valuation Analysis According to Seeking Alpha's dashboard on MIRM, the company is projected to generate roughly ...